Latest Breaking News On - Brii biosciences limited bio - Page 2 : comparemela.com

Brii Biosciences Appoints Dr Brian Alvin Johns as Chief Scientific Officer

DURHAM, N.C., and BEIJING, Jan. 3, 2024 /PRNewswire/ Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company

Brian alvinBriana johnsZhi hongBrii biosciencesBrii bioBrian alvin johnsHemoshear therapeutics incBrii biosciences limited bioBrii biosciences limitedChief scientific officerChief executive officerHemoshear therapeuticsViiv healthcareBiosciences limitedSan francisco bay areaBrii biosciences appoints

Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B

Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

David margolisBrii bioPrnewswire brii biosciences limited bioBrii biosciencesBrii biosciences limited bioBiosciences limitedChief medical officerVir biotechnologyCombination studyFrancisco bay area

Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results

First patient dosed in a PEG-IFN-α controlled BRII-835 + PEG-IFN-α combination Phase 2 study for HBV functional cure First of several studies to investigate the potential of BRII-179 in.

Hong kongBrii bioAsia pacificBrii biosciencesNational medical products administrationVir biotechnology incPrnewswire brii biosciences limited bioDrug administrationBrii biosciences limited bioVaccines incBiosciences limitedGreater chinaMarket authorization applicationVir biotechnologyInvestigational new drugDrug evaluation

Durham biotech Brii to receive $24M for its stake in sale of US drug firm

Durham-based Brii Biosciences will net some $24 million up front and also secured future royalty payments in a deal involving the sale of its share in a biotech that's being acquired by Japan-based pharmaceutical company Shionogi.

San diegoUnited statesQpex biopharmaZhi hongBrii bioBrii biosciencesBrii biosciences limited bioNational medical products administrationBiosciences announces entryDefinitive agreementsEquity interestAcquiring exclusive global rightsBrii biosciences limitedGreater chinaChief executive officer

Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders

/PRNewswire/ Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient.

Lianhong xuBrii bioBrii biosciences limited bioBrii biosciences limited